Oruka Therapeutics (NASDAQ:ORKA – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $45.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 55.82% from the company’s current price.
Several other brokerages also recently commented on ORKA. TD Cowen initiated coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They issued a “buy” rating for the company. Stifel Nicolaus assumed coverage on Oruka Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $49.00 price objective on the stock. Lifesci Capital initiated coverage on Oruka Therapeutics in a research report on Monday, September 16th. They set an “outperform” rating and a $41.00 price objective on the stock. Leerink Partners began coverage on Oruka Therapeutics in a research report on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 target price for the company. Finally, Wedbush assumed coverage on Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $43.17.
Read Our Latest Report on Oruka Therapeutics
Oruka Therapeutics Price Performance
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported ($25.92) EPS for the quarter. As a group, research analysts anticipate that Oruka Therapeutics will post -1.69 earnings per share for the current year.
About Oruka Therapeutics
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.
Featured Articles
- Five stocks we like better than Oruka Therapeutics
- How to Calculate Options Profits
- Caterpillar Stock: Market Points to a Buying Opportunity
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Big Buybacks Announced: 3 Stocks Insiders Are Banking On
- What Does Downgrade Mean in Investing?
- Chipotle Serves Up a Price Dip – The Market Is Buying
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.